Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal ADXBUL:ETR 50 Return-on-Tangible-Asset is 1.60% as of Dec. 2025, which is 1043% above its 10-year median of 0.14. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Etropal AD ranks better than 52.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Etropal AD's annualizedNet Income for the quarter that ended in Dec. 2025 was €0.16 Mil. Etropal AD's average total tangible assets for the quarter that ended in Dec. 2025 was €9.78 Mil. Therefore, Etropal AD's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 1.60%.
The historical rank and industry rank for Etropal AD's Return-on-Tangible-Asset or its related term are showing as below:
XBUL:ETR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -22.72 Med: 0.14 Max: 1.6
Current: 1.6
During the past 13 years, Etropal AD's highest Return-on-Tangible-Asset was 1.60%. The lowest was -22.72%. And the median was 0.14%.
XBUL:ETR's Return-on-Tangible-Asset is ranked better than 52.17% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs XBUL:ETR: 1.60
Etropal AD (XBUL:ETR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Etropal AD Return-on-Tangible-Asset Related Terms
Etropal AD Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Etropal AD's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Etropal AD's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 1.60% mean?
Etropal AD (XBUL:ETR) has a Return-on-Tangible-Asset of 1.60% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Etropal AD and its competitors. This is 1043% above median its historical median of 0.14. According to the industry distribution chart, Etropal AD ranks #408 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 47.8%.
Is Etropal AD's Return-on-Tangible-Asset too high?
Etropal AD's current Return-on-Tangible-Asset of 1.60% is 1043% above median its 10-year median of 0.14. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Etropal AD's value of 1.60% is 79.8% above this industry median. Based on the distribution chart, Etropal AD ranks #408 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #408 out of 853 companies for Return-on-Tangible-Asset. This puts Etropal AD in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.89. Etropal AD's value of 1.60% is 79.8% above this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 0.89, Etropal AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current Return-on-Tangible-Asset of 1.60% is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current Return-on-Tangible-Asset is 1.60%, which is 1043% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.78, compared to a current price of €2.66 — trading 69.7% below its estimated fair value. The current Return-on-Tangible-Asset is 1.60%, which is 1043% above median its 10-year median of 0.14 and 79.8% above the Medical Devices & Instruments industry median of 0.89. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Return-on-Tangible-Asset is 1.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.66 is trading 69.7% below its estimated GF Value™ of €8.78.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Return-on-Tangible-Asset: 1.60% (1043% above median its 10-year median of 0.14)
GF Value™: €8.78 vs. price of €2.66 (69.7% below fair value)
Industry Position: 79.8% above the Medical Devices & Instruments median (#408 of 853)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
